Latest period
$107.20M
YoY change
+417.7%
5Y CAGR
+15.3%
Peak year (2025)
$71.89M
Latest annual
$71.89M
Cash on Hand history chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025
Latest: $71.89M
Cash on Hand growth chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025
Latest: +417.7%
Cash on Hand history table for SELLAS Life Sciences Group (SLS) from 2006 to 2025
| 2025 | $71.89M | +417.7% | +$58.01M | ||
| 2024 | $13.89M | +448.9% | +$11.36M | ||
| 2023 | $2.53M | -85.2% | −$14.60M | ||
| 2022 | $17.13M | -20.2% | −$4.33M | ||
| 2021 | $21.45M | -39.2% | −$13.85M | ||
| 2020 | $35.30M | +385.1% | +$28.02M | ||
| 2019 | $7.28M | +36.4% | +$1.94M | ||
| 2018 | $5.34M | +130.1% | +$3.02M | ||
| 2017 | $2.32M | -87.2% | −$15.76M | ||
| 2016 | $18.08M | -39.2% | −$11.65M | ||
| 2015 | $29.73M | +25.7% | +$6.08M | ||
| 2014 | $23.65M | -50.5% | −$24.14M | ||
| 2013 | $47.79M | +34.7% | +$12.30M | ||
| 2012 | $35.48M | +210.4% | +$24.05M | ||
| 2011 | $11.43M | +65.9% | +$4.54M | ||
| 2010 | $6.89M | +21.2% | +$1.21M | ||
| 2009 | $5.68M | -42.3% | −$4.17M | ||
| 2008 | $9.86M | -15.9% | −$1.86M | ||
| 2007 | $11.71M | +585650.0% | +$11.71M | ||
| 2006 | $2.00K | — | — |
- 2025$71.89M+417.7%
- 2024$13.89M+448.9%
- 2023$2.53M-85.2%
- 2022$17.13M-20.2%
- 2021$21.45M-39.2%
- 2020$35.30M+385.1%
- 2019$7.28M+36.4%
- 2018$5.34M+130.1%
- 2017$2.32M-87.2%
- 2016$18.08M-39.2%
- 2015$29.73M+25.7%
- 2014$23.65M-50.5%
- 2013$47.79M+34.7%
- 2012$35.48M+210.4%
- 2011$11.43M+65.9%
- 2010$6.89M+21.2%
- 2009$5.68M-42.3%
- 2008$9.86M-15.9%
- 2007$11.71M+585650.0%
- 2006$2.00K—
Cash on Hand values are taken from SELLAS Life Sciences Group's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Cash on Hand at SELLAS Life Sciences Group (SLS)
According to SELLAS Life Sciences Group's latest reported financial statements, the company's latest reported cash and short-term investments is $107.20M. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of SELLAS Life Sciences Group (SLS) cash and short-term investments is $71.89M – surged 417.7% year-over-year.
Across 2020–2025 (5 years), SELLAS Life Sciences Group cash and short-term investments produced a CAGR of +15.3% – sustaining 2 straight years of year-over-year growth.
The highest annual cash and short-term investments of $71.89M was reported in 2025. The lowest in the available history was $2.00K in 2006.
SELLAS Life Sciences Group Cash on Hand by Year
SELLAS Life Sciences Group Cash on Hand 2025: $71.89M
SELLAS Life Sciences Group posted cash and short-term investments of $71.89M in 2025, surged 417.7% from 2024. This figure represents the highest annual value in the available history.
SELLAS Life Sciences Group Cash on Hand 2024: $13.89M
In 2024, SELLAS Life Sciences Group reported cash and short-term investments of $13.89M, surged 448.9% from 2023.
SELLAS Life Sciences Group Cash on Hand 2023: $2.53M
SELLAS Life Sciences Group cash and short-term investments in 2023 was $2.53M, plunged 85.2% below 2022.
SELLAS Life Sciences Group Cash on Hand 2022: $17.13M
2022's cash and short-term investments for SELLAS Life Sciences Group came in at $17.13M, declined 20.2% below 2021.
SELLAS Life Sciences Group Cash on Hand 2021: $21.45M
SELLAS Life Sciences Group cash and short-term investments in 2021 was $21.45M.
See more financial history for SELLAS Life Sciences Group (SLS).
Sector peers by Cash on Hand
Healthcare peers of SELLAS Life Sciences Group (SLS), ranked by their latest cash and short-term investments
| $28.12B | |
| $20.10B | |
| $14.56B | |
| $9.13B | |
| $7.27B | |
| $5.74B | |
| $5.26B | |
| $4.24B |
- $28.12B
- $20.10B
- $14.56B
- $9.13B
- $7.27B
- $5.74B
- $5.26B
- $4.24B
Frequently asked questions
SELLAS Life Sciences Group (SLS) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation